These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 20090429

  • 21. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
    Abuissa H, Jones PG, Marso SP, O'Keefe JH.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):821-6. PubMed ID: 16139131
    [Abstract] [Full Text] [Related]

  • 22. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U, Deedwania PC.
    Cardiol Clin; 2008 Nov 06; 26(4):507-26. PubMed ID: 18929228
    [Abstract] [Full Text] [Related]

  • 23. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM.
    Acta Diabetol; 2005 Apr 06; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [Abstract] [Full Text] [Related]

  • 24. [Angiotensin II antagonists versus ACE inhibitors in the treatment of raised blood pressure].
    Andersen RS, Christensen S.
    Ugeskr Laeger; 2001 Dec 10; 163(50):7036-9. PubMed ID: 11794033
    [Abstract] [Full Text] [Related]

  • 25. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 10; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 26. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A, Pedrinelli R, Arzilli F, Abdel-Haq B, Magagna A, Lucarini A, Graziadei L, Nuccorini A, Taddei S.
    Int J Clin Pharmacol Res; 1985 Jul 10; 5(6):429-38. PubMed ID: 3005182
    [Abstract] [Full Text] [Related]

  • 27. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 10; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 28. On target to dual block RAS?
    Papadopoulos DP, Papademetriou V, Makris TK.
    Angiology; 2009 Jan 10; 60(6):739-49. PubMed ID: 19144653
    [Abstract] [Full Text] [Related]

  • 29. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA, Giles TD.
    Rev Cardiovasc Med; 2006 Jan 10; 7(2):45-54. PubMed ID: 16915123
    [Abstract] [Full Text] [Related]

  • 30. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 10; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V.
    J Hypertens Suppl; 2005 Apr 10; 23(1):S9-17. PubMed ID: 15821452
    [Abstract] [Full Text] [Related]

  • 33. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J.
    Diabetes Res Clin Pract; 2007 May 10; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD.
    Rev Cardiovasc Med; 2007 May 10; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [Abstract] [Full Text] [Related]

  • 36. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C, Mastrorilli F, Squasi PA, Gaitani S, Guardigli G, Ferrari R.
    Ital Heart J; 2005 Nov 10; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Management of hypertension in patients with chronic kidney disease and diabetes mellitus.
    Palmer BF.
    Am J Med; 2008 Aug 10; 121(8 Suppl):S16-22. PubMed ID: 18638614
    [Abstract] [Full Text] [Related]

  • 39. Role of angiotensin receptor blockers in the prevention and treatment of arrhythmias.
    Garg S, Narula J, Marelli C, Cesario D.
    Am J Cardiol; 2006 Mar 15; 97(6):921-5. PubMed ID: 16516603
    [Abstract] [Full Text] [Related]

  • 40. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R, Palmer BF.
    Am J Nephrol; 2008 Mar 15; 28(3):372-80. PubMed ID: 18073461
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.